Galapagos NV ADR (GLPG)

$26.86 +0.37 (1.40%)
Market Cap 1.75B
Revenue (ttm) 298.28M
Net Income (ttm) 80.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 26.87%
Debt to Equity Ratio 0.00
Volume 384,300
Avg Vol 297,758
Day's Range N/A - N/A
Shares Out 65.90M
Stochastic %K 97%
Beta 0.16
Analysts Hold
Price Target $28.75

Latest News on GLPG

Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101

Apr 25, 2025, 6:16 PM EDT - 17 hours ago

Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101

Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 11:34 AM EDT - 2 days ago

Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Apr 23, 2025, 4:01 PM EDT - 2 days ago

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Apr 15, 2025, 1:30 AM EDT - 11 days ago

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Mar 27, 2025, 4:01 PM EDT - 4 weeks ago

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Galapagos to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:01 PM EST - 2 months ago

Galapagos to Present at Upcoming Investor Conferences

Disount To Net Cash For A Promising CAR-T Company

Feb 20, 2025, 7:13 AM EST - 2 months ago

Disount To Net Cash For A Promising CAR-T Company

Galapagos receives transparency notification and 13D filing from Tang Capital

Feb 17, 2025, 4:01 PM EST - 2 months ago

Galapagos receives transparency notification and 13D filing from Tang Capital

Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 1:26 PM EST - 2 months ago

Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Feb 12, 2025, 4:01 PM EST - 2 months ago

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Galapagos To Spin Off Innovative Medicines Business

Jan 21, 2025, 12:08 PM EST - 3 months ago

Galapagos To Spin Off Innovative Medicines Business

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Jan 8, 2025, 1:30 AM EST - 3 months ago

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:01 PM EST - 3 months ago

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Dec 7, 2024, 12:30 PM EST - 4 months ago

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Nov 5, 2024, 4:01 PM EST - 6 months ago

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 3:50 PM EDT - 6 months ago

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:01 PM EDT - 6 months ago

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Oct 7, 2024, 1:00 AM EDT - 7 months ago

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Oct 1, 2024, 6:00 AM EDT - 7 months ago

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Galapagos receives transparency notification from EcoR1 Capital

Sep 30, 2024, 4:01 PM EDT - 7 months ago

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from FMR LLC

Sep 3, 2024, 4:01 PM EDT - 8 months ago

Galapagos receives transparency notification from FMR LLC

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Aug 23, 2024, 3:49 PM EDT - 8 months ago

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Aug 23, 2024, 1:00 AM EDT - 8 months ago

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 1:25 PM EDT - 9 months ago

Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Aug 1, 2024, 4:01 PM EDT - 9 months ago

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Galapagos reports half-year 2024 financial results and provides second quarter business update

Aug 1, 2024, 4:01 PM EDT - 9 months ago

Galapagos reports half-year 2024 financial results and provides second quarter business update

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Jun 14, 2024, 4:01 PM EDT - 11 months ago

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

May 30, 2024, 4:01 PM EDT - 11 months ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

ADAP

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 30, 2024, 4:01 PM EDT - 11 months ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

ADAP

Galapagos creates new subscription right plans

May 16, 2024, 4:01 PM EDT - 1 year ago

Galapagos creates new subscription right plans

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.

May 15, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.

Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript

May 4, 2024, 11:51 AM EDT - 1 year ago

Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript

Galapagos reports first quarter 2024 financial results

May 2, 2024, 4:01 PM EDT - 1 year ago

Galapagos reports first quarter 2024 financial results

Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Apr 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Apr 4, 2024, 4:01 PM EDT - 1 year ago

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Mar 26, 2024, 4:01 PM EDT - 1 year ago

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Mar 7, 2024, 11:30 AM EST - 1 year ago

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV (GLPG) Q4 2023 Earnings Call Transcript

Feb 23, 2024, 10:23 AM EST - 1 year ago

Galapagos NV (GLPG) Q4 2023 Earnings Call Transcript

Galapagos announces full year 2023 results and outlook for 2024

Feb 22, 2024, 4:01 PM EST - 1 year ago

Galapagos announces full year 2023 results and outlook for 2024

Galapagos presents at EBMT-EHA annual meeting 2024

Feb 15, 2024, 4:01 PM EST - 1 year ago

Galapagos presents at EBMT-EHA annual meeting 2024

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Jan 31, 2024, 4:01 PM EST - 1 year ago

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

Jan 4, 2024, 4:01 PM EST - 1 year ago

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

TMO

BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

Jan 3, 2024, 4:01 PM EST - 1 year ago

BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Jan 3, 2024, 4:01 PM EST - 1 year ago

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Jan 2, 2024, 1:00 AM EST - 1 year ago

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Dec 19, 2023, 4:01 PM EST - 1 year ago

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Dec 9, 2023, 12:00 PM EST - 1 year ago

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Dec 7, 2023, 4:01 PM EST - 1 year ago

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

Nov 6, 2023, 7:45 AM EST - 1 year ago

Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care